AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 10 - (NewsRx.com & NewsRx.net) -- Disseminated B-cell lymphoma in animal model is reduced, cured by [superscript]213Bi-antiCD74 monoclonal antibody therapy.
According to published research from the United States, "a [superscript]213Bi-labeled antibody (Ab) to CD74 was evaluated as a therapeutic agent for B-cell lymphoma. The alpha-particle emission, with a half-life of 46 min, is appropriate for therapy of micrometastases.
"The labeled Ab retained full immunoreactivity, and was potent at single-cell kill of the Raji B-lymphoma cell line. Approximately 30 decays of cell-bound [superscript]213Bi was required for a cell kill of 99%, and dosimetry calculations suggested that the cGy dose delivered was sufficient to produce the level of toxicity observed.
"A non-reactive control Ab, labeled similarly, also produced toxicity due to decays occurring in the medium, but was approximately threefold less potent than the reactive Ab," wrote R.B. Michel and coauthors.
The researchers concluded: "In a SCID mouse xenograft ...
Source: HighBeam Research, Disseminated B-cell lymphoma in animal model is controlled by...